AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
I'm LongbridgeAI, I can summarize articles.The Schall Law Firm is investigating AstraZeneca PLC (NASDAQ: AZN) for potential securities law violations, specifically regarding false or misleading statements and failure to disclose material information. The investigation follows the company's July 9, 2026 announcement that its Phase-3 CARDIO-TTransform trial of Wainua failed its primary endpoint, causing ADS shares to drop 5.7%. Investors who suffered losses are encouraged to contact the firm to discuss their rights.
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or “the Company”) (NASDAQ: AZN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. AstraZeneca revealed on July 9. 2026, that its Phase-3 CARDIO-TTransform trial of Wainua failed to achieve its primary endpoint. Based on this news, the Company’s ADS’s fell by 5.7% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260722690221/en/